South Korea
· Delayed Price · Currency is KRW GeneMatrix Statistics
Total Valuation
GeneMatrix has a market cap or net worth of KRW 59.34 billion.
| Market Cap | 59.34B |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
GeneMatrix has 20.39 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 20.39M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +10.69% |
| Owned by Insiders (%) | 15.95% |
| Owned by Institutions (%) | 0.02% |
| Float | 17.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.42 |
| PB Ratio | 3.50 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.02, with a Debt / Equity ratio of 0.70.
| Current Ratio | 2.02 |
| Quick Ratio | 1.80 |
| Debt / Equity | 0.70 |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.74 |
| Interest Coverage | -4.12 |
Financial Efficiency
Return on equity (ROE) is -15.62% and return on invested capital (ROIC) is -6.71%.
| Return on Equity (ROE) | -15.62% |
| Return on Assets (ROA) | -6.05% |
| Return on Capital (ROIC) | -6.71% |
| Revenue Per Employee | 152.32M |
| Profits Per Employee | -67.52M |
| Employee Count | 31 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 2.35 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +5.43% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +5.43% |
| 50-Day Moving Average | 3,242.70 |
| 200-Day Moving Average | 2,907.73 |
| Relative Strength Index (RSI) | 42.35 |
| Average Volume (20 Days) | 286,928 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GeneMatrix had revenue of KRW 4.72 billion and -2.09 billion in losses. Loss per share was -123.85.
| Revenue | 4.72B |
| Gross Profit | 1.79B |
| Operating Income | -2.63B |
| Pretax Income | -1.97B |
| Net Income | -2.09B |
| EBITDA | -2.14B |
| EBIT | -2.63B |
| Loss Per Share | -123.85 |
Balance Sheet
The company has 11.87 billion in cash and 10.83 billion in debt, giving a net cash position of 1.04 billion or 50.89 per share.
| Cash & Cash Equivalents | 11.87B |
| Total Debt | 10.83B |
| Net Cash | 1.04B |
| Net Cash Per Share | 50.89 |
| Equity (Book Value) | 15.53B |
| Book Value Per Share | 830.38 |
| Working Capital | 8.19B |
Cash Flow
In the last 12 months, operating cash flow was -2.24 billion and capital expenditures -651.33 million, giving a free cash flow of -2.89 billion.
| Operating Cash Flow | -2.24B |
| Capital Expenditures | -651.33M |
| Free Cash Flow | -2.89B |
| FCF Per Share | -141.95 |
Margins
Gross margin is 37.83%, with operating and profit margins of -55.67% and -44.33%.
| Gross Margin | 37.83% |
| Operating Margin | -55.67% |
| Pretax Margin | -41.71% |
| Profit Margin | -44.33% |
| EBITDA Margin | -45.41% |
| EBIT Margin | -55.67% |
| FCF Margin | -61.31% |
Dividends & Yields
GeneMatrix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -65.60% |
| Shareholder Yield | -65.60% |
| Earnings Yield | -4.26% |
| FCF Yield | -4.88% |
Stock Splits
The last stock split was on July 24, 2018. It was a forward split with a ratio of 1.5.
| Last Split Date | Jul 24, 2018 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
GeneMatrix has an Altman Z-Score of 2.17. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.17 |
| Piotroski F-Score | n/a |